Contact information
Emma Culver
BSc (Hons), MBChB, MRCP, DPhil
Professor Head for Hepatology at the John Radcliffe Hospital in Oxford, the Chair for the British Liver Association for Immune Mediated Liver Disease, Scientific Committee and Governing Board for EASL and Research Council for UEG
- Wellcome Trust Clinical Research Fellow, University of Oxford, Oxford, UK.
- Professor Emma Culver is the Head for Hepatology at the John Radcliffe Hospital in Oxford
Professor Emma Culver is the Head for Hepatology at the John Radcliffe Hospital in Oxford, the Chair for the British Liver Association for Immune Mediated Liver Disease, Scientific Committee and Governing Board for EASL and Research Council for UEG
She set up and co-ordinated the IgG4-RD Study in Oxford during her Academic Clinical Fellowship (2010) and Wellcome Trust Clinical Research Fellowship (DPhil 2011-2015). Her PhD work focussed on the natural history and immunological drivers of IgG4-RD. Her NIHR BRC Oxford Clinical Lectureship (2018-) centred on the fibrotic mechanisms of this disease. She runs the Oxford Autoimmune Liver Disease service with specialist IgG4, PSC and autoimmune liver clinics, and runs a regional autoimmune liver disease MDT, and a national Oxford-London IgG4 MDT.
She is Chair of UK IgG4 and on the Steering Committee for UK PSC, and a member of the International IgG4-RD, PSC and AIH Study Groups.
Recent publications
The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view.
Journal article
Jones DEJ. et al, (2026), Nature reviews. Gastroenterology & hepatology, 23, 368 - 369
Efficacy and Safety of Obexelimab to Treat IgG4-Related Disease: Protocol for a Global, Randomized, Placebo-Controlled Trial.
Journal article
Culver EL. et al, (2026), Rheumatology and therapy
Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid.
Journal article
Dunn S. et al, (2026), BMJ open, 16
Pruritus is common in primary sclerosing cholangitis, persists over time, and its intensity is associated with disease severity: a multicentre, prospective observational study.
Journal article
Hussain N. et al, (2025), Hepatology (Baltimore, Md.)
Adherence to United European Gastroenterology Guidelines on Diagnosis and Therapy of Immunoglobulin-G4-Related Digestive Disease.
Journal article
Vujasinovic M. et al, (2025), United European gastroenterology journal, 13, 1583 - 1592
